April 2024
1. STEMKENS R, Mouhdad C, Franssen EJF, Touw D, et al
   Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations.
   J Antimicrob Chemother. 2024 Apr 6:dkae105. doi: 10.1093.
   

   >> Share

   
   
2. VAN INGEN J
   Why do we use 100 mg of clofazimine in TB and NTM treatment?
   J Antimicrob Chemother. 2024;79:697-702.
   

   >> Share

   
   March 2024
3. YUNIVITA V, Gafar F, Santoso P, Chaidir L, et al
   Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
   J Antimicrob Chemother. 2024 Mar 9:dkae057. doi: 10.1093.
   

   >> Share

   
   December 2023
4. COMBRINCK J, Tshavhungwe P, Rohlwink U, Enslin N, et al
   Rifampicin and protein concentrations in paired spinal versus ventricular cerebrospinal fluid samples of children with tuberculous meningitis.
   J Antimicrob Chemother. 2023 Dec 15:dkad371. doi: 10.1093.
   

   >> Share

   
   September 2023
5. MOK S, Roycroft E, Flanagan PR, Wagener J, et al
   Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
   J Antimicrob Chemother. 2023 Sep 23:dkad252. doi: 10.1093.
   

   >> Share

   
   February 2023
6. GUMBO T, Srivastava S, Deshpande D, Pasipanodya JG, et al
   Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.
   J Antimicrob Chemother. 2023 Feb 16:dkad029. doi: 10.1093.
   

   >> Share

   
   June 2022
7. GAUSI K, Chirehwa M, Ignatius EH, Court R, et al
   Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
   J Antimicrob Chemother. 2022 Jun 9. pii: 6604654. doi: 10.1093.
   

   >> Share

   
   April 2022
8. LOPEZ-VARELA E, Abulfathi AA, Strydom N, Goussard P, et al
   Drug concentration at the site of disease in children with pulmonary tuberculosis.
   J Antimicrob Chemother. 2022 Apr 25. pii: 6573919. doi: 10.1093.
   

   >> Share

   
   March 2022
9. MUDDE SE, Upton AM, Lenaerts A, Bax HI, et al
   Delamanid or pretomanid? A Solomonic judgement!
   J Antimicrob Chemother. 2022;77:880-902.
   

   >> Share

   
   
10. BATESON A, Ortiz Canseco J, McHugh TD, Witney AA, et al
    Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
    J Antimicrob Chemother. 2022 Mar 9. pii: 6544883. doi: 10.1093.
    

    >> Share

    
    
11. UPTON CM, Steele CI, Maartens G, Diacon AH, et al
    Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB).
    J Antimicrob Chemother. 2022 Mar 8. pii: 6543975. doi: 10.1093.
    

    >> Share

    
    February 2022
12. WASSERMAN S, Brust JCM, Abdelwahab MT, Little F, et al
    Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study.
    J Antimicrob Chemother. 2022 Feb 2. pii: 6520540. doi: 10.1093.
    

    >> Share

    
    January 2022
13. KIESWETTER NS, Ozturk M, Hlaka L, Chia JE, et al
    Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to Mycobacterium tuberculosis infection.
    J Antimicrob Chemother. 2022 Jan 25. pii: 6515318. doi: 10.1093.
    

    >> Share

    
    November 2021
14. CHEUNG CY, McNeil MB, Cook GM
    Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis infection.
    J Antimicrob Chemother. 2021 Nov 28. pii: 6445137. doi: 10.1093.
    

    >> Share

    
    October 2021
15. SUNDELL J, Bienvenu E, Abelo A, Ashton M, et al
    Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
    J Antimicrob Chemother. 2021;76:2950-2957.
    

    >> Share

    
    February 2021
16. RAWIZZA HE, Oladokun R, Ejeliogu E, Oguche S, et al
    Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART.
    J Antimicrob Chemother. 2021;76:710-717.
    

    >> Share

    
    December 2020
17. ALGHAMDI WA, Al-Shaer MH, Kipiani M, Barbakadze K, et al
    Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
    J Antimicrob Chemother. 2020 Dec 30. pii: 6055881. doi: 10.1093.
    

    >> Share

    
    
18. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
    Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.
    J Antimicrob Chemother. 2020 Dec 29. pii: 6055076. doi: 10.1093.
    

    >> Share

    
    
19. BLACKMAN A, Morrison B, Maruri F, van der Heijden Y, et al
    Re-evaluation of a novel resistance mutation in eccC5 of the ESX-5 secretion system in ofloxacin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2020 Dec 23. pii: 6046147. doi: 10.1093.
    

    >> Share

    
    
20. TAHSEEN S, vanDeun A, de Jong BC, Decroo T, et al
    Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?
    J Antimicrob Chemother. 2020 Dec 1. pii: 6015577. doi: 10.1093.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share